Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant CCN2 (Pamrevlumab Biosimilar) antibody

This anti-CCN2 (Pamrevlumab Biosimilar) antibody is a Human Monoclonal antibody detecting CCN2 (Pamrevlumab Biosimilar) in . Suitable for Human.
Catalog No. ABIN7597895

Quick Overview for Recombinant CCN2 (Pamrevlumab Biosimilar) antibody (ABIN7597895)

Target

CCN2 (Pamrevlumab Biosimilar)

Antibody Type

Recombinant Antibody

Reactivity

Human

Host

  • 4
Human

Clonality

  • 4
Monoclonal

Conjugate

  • 3
  • 1
This CCN2 (Pamrevlumab Biosimilar) antibody is un-conjugated

Application

Please inquire

Grade

Research Grade
  • Expression System

    Mammalian cells

    Purpose

    Research Grade Pamrevlumab Biosimilar Antibody

    Specificity

    IGFBP8, IGF-binding protein 8, IBP-8, CTGF, HCS24, CCN family member 2, CCN2, Cellular communication network factor 2, Hypertrophic chondrocyte-specific protein 24, Connective tissue growth factor, Insulin-like growth factor-binding protein 8, IGFBP-8

    Purification

    Protein A or G purified from cell culture supernatant.

    Purity

    >95 % by SDS-PAGE.

    Isotype

    IgG1 kappa
  • Restrictions

    For Research Use only
  • Format

    Liquid

    Concentration

    4.35 mg/mL

    Buffer

    0.01M PBS, pH 7.4.

    Storage

    4 °C,-20 °C,-80 °C

    Storage Comment

    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

    Expiry Date

    12 months
  • Target

    CCN2 (Pamrevlumab Biosimilar)

    Alternative Name

    Pamrevlumab Biosimilar

    Target Type

    Biosimilar

    Background

    IGFBP8, IGF-binding protein 8, IBP-8, CTGF, HCS24, CCN family member 2, CCN2, Cellular communication network factor 2, Hypertrophic chondrocyte-specific protein 24, Connective tissue growth factor, Insulin-like growth factor-binding protein 8, IGFBP-8

    UniProt

    P29279

    CAS-No

    946415-13-0
You are here:
Chat with us!